Small Players Ruling the Hard Game: SiRNA in Bone Regeneration

Journal of Bone and Mineral Research

Volumn 31, Issue 3, 2016, Pages 475-487

  Ghadakzadeh, Saber ^a,b   Mekhail, Mina ^b   Aoude, Ahmed ^b   Hamdy, Reggie ^a,b   Tabrizian, Maryam ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

BONE TISSUE ENGINEERING; DELIVERY SYSTEMS; FRACTURE HEALING; GENE THERAPY; NONUNION BONE HEALING; OLIGOTHERAPEUTIC; SMALL INTERFERING RNA

Indexed keywords

ANGIOGENIC FACTOR; LIPID; POLYMER; SMALL INTERFERING RNA;

BONE REGENERATION; DRUG DELIVERY SYSTEM; HEALTH CARE SYSTEM; HUMAN; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL INJURY; NONHUMAN; REVIEW; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; METABOLISM;

ANIMALS; BONE REGENERATION; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; MODELS, BIOLOGICAL; RNA, SMALL INTERFERING;

EID: 84960389324     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2816     Document Type: Review

References (121)

1. Luo J, Sun MH, Kang Q, et al., Gene therapy for bone regeneration. Curr Gene Ther. 2005; 5 (2): 167-79.
2. Marsell R, Einhorn TA., The biology of fracture healing. Injury. 2011; 42 (6): 551-5.
3. Giannoudis PV, Einhorn TA, Marsh D., Fracture healing: the diamond concept. Injury. 2007; 38 Suppl 4: S3-6.
4. Einhorn TA, Gerstenfeld LC., Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015; 11 (1): 45-54.
5. Im GI,. Nonviral gene transfer strategies to promote bone regeneration. J Biomed Mater Res A. 2013; 101 (10): 3009-18.
6. Balmayor ER., Targeted delivery as key for the success of small osteoinductive molecules. Adv Drug Deliv Rev. 2015 Nov 1; 94: 13-27.
7. Polyzois VD, Stathopoulos IP, Lampropoulou-Adamidou K, Vasiliadis ES, Vlamis J, Pneumaticos SG., Strategies for managing bone defects of the lower extremity. Clin Podiatr Med Surg. 2014; 31 (4): 577-84.
8. Sen MK, Miclau T., Autologous iliac crest bone graft: should it still be the gold standard for treating nonunions ? Injury. 2007; 38 Suppl 1: S75-80.
9. Myeroff C, Archdeacon M., Autogenous bone graft: donor sites and techniques. J Bone Joint Surg Am. 2011; 93 (23): 2227-36.
10. Tare RS, Kanczler J, Aarvold A, Jones AM, Dunlop DG, Oreffo RO., Skeletal stem cells and bone regeneration: translational strategies from bench to clinic. Proc Inst Mech Eng H. 2010; 224 (12): 1455-70.
11. Santos JL, Pandita D, Rodrigues J, Pêgo AP, Granja PL, Tomás H., Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration. Curr Gene Ther. 2011; 11 (1): 46-57.
12. Simpson AH, Mills L, Noble B., The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br. 2006; 88 (6): 701-5.
13. Aagaard L, Rossi JJ, RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007; 59 (2-3): 75-86.
14. Gautschi OP, Frey SP, Zellweger R., Bone morphogenetic proteins in clinical applications. ANZ J Surg. 2007; 77 (8): 626-31.
15. Haidar ZS, Hamdy RC, Tabrizian M., Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part A: Current challenges in BMP delivery. Biotechnol Lett. 2009; 31 (12): 1817-24.
16. Haidar ZS, Hamdy RC, Tabrizian M., Delivery of recombinant bone morphogenetic proteins for bone regeneration and repair. Part B: Delivery systems for BMPs in orthopaedic and craniofacial tissue engineering. Biotechnol Lett. 2009; 31 (12): 1825-35.
17. Croteau S, Rauch F, Silvestri A, Hamdy RC., Bone morphogenetic proteins in orthopedics: from basic science to clinical practice. Orthopedics. 1999; 22 (7): 686-95; quiz 696-7.
18. Evans CH., Gene therapy for bone healing. Expert Rev Mol Med. 2010; 12: e18.
19. Epstein NE., Complications due to the use of BMP/INFUSE in spine surgery: the evidence continues to mount. Surg Neurol Int. 2013; 4 (Suppl 5): S343-52.
20. Choi YJ, Lee JY, Park JH, et al., The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. Biomaterials. 2010; 31 (28): 7226-38.
21. Lo KW, Ashe KM, Kan HM, Laurencin CT., The role of small molecules in musculoskeletal regeneration. Regen Med. 2012; 7 (4): 535-49.
22. Lo KW, Ulery BD, Kan HM, Ashe KM, Laurencin CT., Evaluating the feasibility of utilizing the small molecule phenamil as a novel biofactor for bone regenerative engineering. J Tissue Eng Regen Med. 2014; 8 (9): 728-36.
23. Lo KW, Kan HM, Laurencin CT., Short-term administration of small molecule phenamil induced a protracted osteogenic effect on osteoblast-like MC3T3-E1 cells. J Tissue Eng Regen Med. Forthcoming. Epub 2013 Jul 30. DOI: 10.1002/term.1786.
24. Evans CH., Gene delivery to bone. Adv Drug Deliv Rev. 2012; 64 (12): 1331-40.
25. Balmayor ER, van Griensven M., Gene therapy for bone engineering. Front Bioeng Biotechnol. 2015; 3: 9.
26. Evans CH, Huard J., Gene therapy approaches to regenerating the musculoskeletal system. Nat Rev Rheumatol. 2015; 11 (4): 234-42.
27. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G., Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015; 87: 108-19.
28. Lam JK, Chow MY, Zhang Y, Leung SW., siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015; 4: e252.
29. Dykxhoorn DM, Novina CD, Sharp PA., Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003; 4 (6): 457-67.
30. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK., RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev. 2003; 67 (4): 657-85.
31. Bender J., A vicious cycle: RNA silencing and DNA methylation in plants. Cell. 2001; 106 (2): 129-32.
32. Bernstein E, Caudy AA, Hammond SM, Hannon GJ., Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001; 409 (6818): 363-6.
33. Fagard M, Vaucheret H., (Trans)gene silencing in plants: how many mechanisms ? Annu Rev Plant Physiol Plant Mol Biol. 2000; 51: 167-94.
34. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T., Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001; 20 (23): 6877-88.
35. tenOever BR,. RNA viruses and the host microRNA machinery. Nat Rev Microbiol. 2013; 11 (3): 169-80.
36. Arroyo JD, Gallichotte EN, Tewari M., Systematic design and functional analysis of artificial microRNAs. Nucleic Acids Res. 2014; 42 (9): 6064-77.
37. Hammond SM, Caudy AA, Hannon GJ., Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet. 2001; 2 (2): 110-9.
38. Sharp PA., RNA interference-2001. Genes Dev. 2001; 15 (5): 485-90.
39. Bernstein E, Denli AM, Hannon GJ., The rest is silence. RNA. 2001; 7 (11): 1509-21.
40. Wittrup A, Lieberman J., Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015; 16 (9): 543-52.
41. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS., Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 2002; 16 (8): 948-58.
42. Moore CB, Guthrie EH, Huang MT, Taxman DJ., Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol. 2010; 629: 141-58.
43. Davidson BL, McCray PB Jr,. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011; 12 (5): 329-40.
44. Borel F, Kay Ma, Mueller C,. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther. 2014; 22 (4): 692-701.
45. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391 (6669): 806-11.
46. McBride JL, Boudreau RL, Harper SQ, et al., Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci U S A. 2008; 105 (15): 5868-73.
47. Chang N, Xiu L, Li L,. Sphingosine 1-phosphate receptors negatively regulate collagen type I/III expression in human bone marrow-derived mesenchymal stem cell. J Cell Biochem. 2014; 115 (2): 359-67.
48. Cho YA, Jue SS, Bae WJ, et al., PIN1 inhibition suppresses osteoclast differentiation and inflammatory responses. J Dent Res. 2015; 94 (2): 371-80.
49. de Gorter DJ, van Dinther M, Korchynskyi O, ten Dijke P. Biphasic effects of transforming growth factor beta on bone morphogenetic protein-induced osteoblast differentiation. J Bone Miner Res. 2011; 26 (6): 1178-87.
50. Deng M, Liu P, Xiao H, et al., Improving the osteogenic efficacy of BMP2 with mechano growth factor by regulating the signaling events in BMP pathway. Cell Tissue Res. 2015 Sep; 361 (3): 723-31.
51. Du Z, Wang L, Zhao Y, et al., Sympathetic denervation-induced MSC mobilization in distraction osteogenesis associates with inhibition of MSC migration and osteogenesis by norepinephrine/adrb3. PLoS One. 2014; 9 (8): e105976.
52. Guérit D, Brondello JM, Chuchana P, et al., FOXO3A regulation by miRNA-29a controls chondrogenic differentiation of mesenchymal stem cells and cartilage formation. Stem Cells Dev. 2014; 23 (11): 1195-205.
53. Khaddam M, Huet E, Vallée B, et al., EMMPRIN/CD147 deficiency disturbs ameloblast-odontoblast cross-talk and delays enamel mineralization. Bone. 2014; 66: 256-66.
54. Kong X, Liu Y, Ye R, et al., GSK3beta is a checkpoint for TNF-alpha-mediated impaired osteogenic differentiation of mesenchymal stem cells in inflammatory microenvironments. Biochim Biophys Acta. 2013; 1830 (11): 5119-29.
55. Kook SH, Jeon YM, Lim SS, et al., Fibroblast growth factor-4 enhances proliferation of mouse embryonic stem cells via activation of c-Jun signaling. PLoS One. 2013; 8 (8): e71641.
56. Kook SH, Lim SS, Cho ES, et al., COMP-angiopoietin 1 increases proliferation, differentiation, and migration of stem-like cells through Tie-2-mediated activation of p38 MAPK and PI3K/Akt signal transduction pathways. Biochem Biophys Res Commun. 2014; 455 (3-4): 371-7.
57. Lee SI, Kim GT, Kim HJ, Park SH, Kim EC., NOD2 mediates odontoblast differentiation and RANKL expression. J Dent Res. 2014; 93 (7): 678-84.
58. Levi B, Hyun JS, Nelson ER, et al., Nonintegrating knockdown and customized scaffold design enhances human adipose-derived stem cells in skeletal repair. Stem Cells. 2011; 29 (12): 2018-29.
59. Oh YI, Kim JH, Kang CW., Protective effect of short-term treatment with parathyroid hormone 1-34 on oxidative stress is involved in insulin-like growth factor-I and nuclear factor erythroid 2-related factor 2 in rat bone marrow derived mesenchymal stem cells. Regul Pept. 2014; 189: 1-10.
60. Ozeki N, Kawai R, Yamaguchi H, et al., IL-1beta-induced matrix metalloproteinase-13 is activated by a disintegrin and metalloprotease-28-regulated proliferation of human osteoblast-like cells. Exp Cell Res. 2014; 323 (1): 165-77.
61. Shih YR, Hwang Y, Phadke A, et al., Calcium phosphate-bearing matrices induce osteogenic differentiation of stem cells through adenosine signaling. Proc Natl Acad Sci U S A. 2014; 111 (3): 990-5.
62. Singhatanadgit W, Salih V, Olsen I., RNA interference of the BMPR-IB gene blocks BMP-2-induced osteogenic gene expression in human bone cells. Cell Biol Int. 2008; 32 (11): 1362-70.
63. Someya H, Fujiwara H, Nagata K, et al., Thymosin beta 4 is associated with RUNX2 expression through the Smad and Akt signaling pathways in mouse dental epithelial cells. Int J Mol Med. 2015; 35 (5): 1169-78.
64. Son GY, Yang YM, Park WS, Chang I, Shin DM., Hypotonic stress induces RANKL via transient receptor potential melastatin 3 (TRPM3) and vaniloid 4 (TRPV4) in human PDL cells. J Dent Res. 2015; 94 (3): 473-81.
65. Song K, Krause C, Shi S, et al., Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem. 2010; 285 (16): 12169-80.
66. Tiaden AN, Breiden M, Mirsaidi A, et al., Human serine protease HTRA1 positively regulates osteogenesis of human bone marrow-derived mesenchymal stem cells and mineralization of differentiating bone-forming cells through the modulation of extracellular matrix protein. Stem Cells. 2012; 30 (10): 2271-82.
67. Xu J, Yu B, Hong C, Wang CY., KDM6B epigenetically regulates odontogenic differentiation of dental mesenchymal stem cells. Int J Oral Sci. 2013; 5 (4): 200-5.
68. Yan J, Zhang C, Zhao Y, et al., Non-viral oligonucleotide antimiR-138 delivery to mesenchymal stem cell sheets and the effect on osteogenesis. Biomaterials. 2014; 35 (27): 7734-49.
69. Yeh Y, Yang Y, Yuan K., Importance of CD44 in the proliferation and mineralization of periodontal ligament cells. J Periodontal Res. 2014; 49 (6): 827-35.
70. Zhang W, Liu N, Shi H, et al., Upregulation of BMSCs osteogenesis by positively-charged tertiary amines on polymeric implants via charge/iNOS signaling pathway. Sci Rep. 2015; 5: 9369.
71. Nguyen MK, Jeon O, Krebs MD, Schapira D, Alsberg E., Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation. Biomaterials. 2014; 35 (24): 6278-86.
72. Kanasty R, Dorkin JR, Vegas A, Anderson D., Delivery materials for siRNA therapeutics. Nat Mater. 2013; 12 (11): 967-77.
73. Gavrilov K, Saltzman WM., Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012; 85 (2): 187-200.
74. Krebs MD, Jeon O, Alsberg E., Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels. J Am Chem Soc. 2009; 131 (26): 9204-6.
75. Krebs MD, Alsberg E., Localized, targeted, and sustained siRNA delivery. Chemistry. 2011; 17 (11): 3054-62.
76. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA., Polymers for drug delivery systems. Annu Rev Chem Biomol Eng. 2010; 1: 149-73.
77. Huynh CT, Nguyen MK, Tonga GY, Longé L, Rotello VM, Alsberg E., Photocleavable hydrogels for light-triggered siRNA release. Adv Healthc Mater. 2016 Feb; 5 (3): 305-10.
78. Whitehead KA, Langer R, Anderson DG., Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8 (2): 129-38.
79. Makadia HK, Siegel SJ., Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011; 3 (3): 1377-97.
80. Hong L, Wei N, Joshi V, et al., Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A. 2012; 18 (7-8): 775-84.
81. Wang Y, Tran KK, Shen H, Grainger DW., Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials. 2012; 33 (33): 8540-7.
82. Nguyen K, Dang PN, Alsberg E., Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells. Acta Biomater. 2013; 9 (1): 4487-95.
83. Zhang Y, Wei L, Miron RJ, Zhang Q, Bian Z., Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J Dent Res. 2014; 93 (11): 1095-100.
84. Ulbrich K, Subr V, Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev. 2010; 62 (2): 150-66.
85. Wang D, Sima M, Mosley RL, et al., Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl) methacrylamide copolymers. Mol Pharm. 2006; 3 (6): 717-25.
86. Zhang Y, Wei L, Miron RJ, Shi B, Bian Z., Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression. J Bone Miner Res. 2015; 30 (2): 286-96.
87. Minakuchi Y, Takeshita F, Kosaka N, et al., Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res. 2004; 32 (13): e109.
88. Kawakami Y, Ii M, Matsumoto T, et al., A small interfering RNA targeting Lnk accelerates bone fracture healing with early neovascularization. Lab Invest. 2013; 93 (9): 1036-53.
89. Rios CN, Skoracki RJ, Mathur AB., GNAS1 and PHD2 short-interfering RNA support bone regeneration in vitro and in an in vivo sheep model. Clin Orthop Relat Res. 2012; 470 (9): 2541-53.
90. Jia S, Yang X, Song W, et al., Incorporation of osteogenic and angiogenic small interfering RNAs into chitosan sponge for bone tissue engineering. Int J Nanomedicine. 2014; 9: 5307-16.
91. Xu Y, Mirmalek-Sani SH, Yang X, Zhang J, Oreffo RO., The use of small interfering RNAs to inhibit adipocyte differentiation in human preadipocytes and fetal-femur-derived mesenchymal cells. Exp Cell Res. 2006; 312 (10): 1856-64.
92. Kwong FN, Richardson SM, Evans CH, Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells. Arthritis Res Ther. 2008; 10 (3): R65.
93. Chen E, Tang MK, Yao Y, et al., Silencing BRE expression in human umbilical cord perivascular (HUCPV) progenitor cells accelerates osteogenic and chondrogenic differentiation. PLoS One. 2013; 8 (7): e67896.
94. Zhang G, Guo B, Wu H, et al., A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012; 18 (2): 307-14.
95. Liang C, Guo B, Wu H, et al., Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med. 2015; 21 (3): 288-94.
96. Fulmer T., Curiously strong lipidoids. SciBX. 2010; 3 (2). Epub 2010 Jan 14. DOI: 10.1038/scibx.2010.34.
97. Ramasubramanian A, Jeeawoody S, Yang F., Gene delivery of osteoinductive signals to a human fetal osteoblast cell line induces cell death in a dose-dependent manner. Drug Deliv Transl Res. 2015; 5 (2): 160-7.
98. Cho SW, Goldberg M, Son SM, et al., Lipid-like nanoparticles for small interfering RNA delivery to endothelial cells. Adv Funct Mater. 2009; 19 (19): 3112-8.
99. El-Fiqi A, Kim TH, Kim M, et al., Capacity of mesoporous bioactive glass nanoparticles to deliver therapeutic molecules. Nanoscale. 2012; 4 (23): 7475-88.
100. Jackson AL, Linsley PS., Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010; 9 (1): 57-67.
101. Caffrey DR, Zhao J, Song Z, et al., siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS One. 2011; 6 (7): e21503.
102. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I., Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005; 23 (4): 457-62.
103. Xavier JR, Thakur T, Desai P, et al., Bioactive nanoengineered hydrogels for bone tissue engineering: a growth-factor-free approach. ACS Nano. 2015; 9 (3): 3109-18.
104. Fu S, Ni P, Wang B, et al., Injectable and thermo-sensitive PEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration. Biomaterials. 2012; 33 (19): 4801-9.
105. Mekhail M, Tabrizian M., Injectable chitosan-based scaffolds in regenerative medicine and their clinical translatability. Adv Healthc Mater. 2014; 3 (10): 1529-45.
106. Nayef L, Mekhail M, Benameur L, Rendon JS, Hamdy R, Tabrizian M., A combinatorial approach towards achieving an injectable, self-contained, phosphate-releasing scaffold for promoting biomineralization in critical size bone defects. Acta Biomater. 2016; 29: 389-97.
107. Low SA, Yang J, Kopecek J., Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics. Bioconjug Chem. 2014; 25 (11): 2012-20.
108. Jiang T, Yu X, Carbone EJ, Nelson C, Kan HM, Lo KW,. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications. Int J Pharm. 2014; 475 (1-2): 547-57.
109. Ossipov DA., Bisphosphonate-modified biomaterials for drug delivery and bone tissue engineering. Expert Opin Drug Deliv. 2015; 12 (9): 1443-58.
110. Hankenson KD, Dishowitz M, Gray C, Schenker M., Angiogenesis in bone regeneration. Injury. 2011; 42 (6): 556-61.
111. Wan C, Allen TM, Cullis PR., Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv Transl Res. 2014; 4 (1): 74-83.
112. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T., In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003; 24 (7): 1121-31.
113. Xue HY, Liu S, Wong HL,. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond). 2014; 9 (2): 295-312.
114. Davis ME, Zuckerman JE, Choi CH, et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464 (7291): 1067-70.
115. Lappalainen K, Jääskeläinen I, Syrjänen K, Urtti A, Syrjänen S., Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res. 1994; 11 (8): 1127-31.
116. Xue HY, Guo P, Wen WC, Wong HL., Lipid-based nanocarriers for RNA delivery. Curr Pharm Des. 2015; 21 (22): 3140-7.
117. Lv H, Zhang S, Wang B, Cui S, Yan J., Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release. 2006; 114 (1): 100-9.
118. World of RNAi Therapeutics [Internet]. Available from: https://www.google.com/maps/d/viewer?mid=zr-Ht4ReTX3o.kFQo-CkRb9AQ&hl=en-US.
119. Aigner A., Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol. 2006; 124 (1): 12-25.
120. Gondi CS, Rao JS., Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol. 2009; 220 (2): 285-91.
121. Grivas TB, Magnissalis EA,. The use of twin-ring Ilizarov external fixator constructs: application and biomechanical proof-of principle with possible clinical indications. J Orthop Surg Res. 2011; 6: 41.